ARTICLE
25 September 2013

Roche Not To Pursue Breast Cancer Drug ‘Herceptin’ Patent In India

SO
S&A Law Offices

Contributor

S&A Law Offices is a full-service law firm comprising experienced, well-recognized and accomplished professionals. S&A Law Offices aims to provide its clients (both domestic and international) with top-quality counsel and legal insights, which combines the Firm's innovative approach with comprehensive expertise across industries and a broad spectrum of modalities. Being a full-service law firm, we take pride in having the capability of providing impeccable legal solutions across various practice areas and industries and makes an endeavor to provide a 360 degree legal solution. With registered office at Gurugram and other strategically located offices in New Delhi, Mumbai, and Bengaluru, along with associate offices across India, S&A is fully equipped to provide legal services on a pan-India basis.
The Swiss pharmaceutical giant ‘Roche Holding AG’ has decided not to pursue the patent no. 205534 granted in India for breast cancer drug Herceptin which was otherwise valid till 2019.
India Intellectual Property

The Swiss pharmaceutical giant 'Roche Holding AG' has decided not to pursue the patent no. 205534 granted in India for breast cancer drug Herceptin which was otherwise valid till 2019.

As per the Indian Patent Office the 15th year Annuity for the maintenance of the patent was due on 03.05.2013, however the same was not paid on time due to which the patent ceased on 03.05.2013. Though the company still had time till 03.11.2013 to pay the fee and claim its patent, provided a requested for an extension of time was made in Form-4 before 03.05.2013. Assuming that this provision does not exist for this company anymore, the Patentee still has an option to file an application under Section 60 of the Patents Act, 1970 for "restoration of a lapsed patent".

As reported by the Economic Times (VYA RAJAGOPAL, ET Bureau Aug 16, 2013, 03.26AM IST) Roche let the patent for Herceptin lapse in May this year, however, it will continue to enforce all other patents in India and remains committed to working with the Indian government.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More